Skip to main content

Table 1 Patient characteristics (n = 19)

From: Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn’s disease: a cross-sectional study

General characteristics

Age, years

55 (21–71)

Female, n (%)

16 (84)

BMI, kg/m2

25 (21–37)

Current smoker, n (%)

5 (26)

Creatinin, µmol/L

74 (52–98)

eGFR, ml/min/1.73 m2

86 (66–152)

Haemoglobin, mmol/L

8.2 (6.4–9.5)

Erythrocyte folate, nmol/L

1630 (728–2283)

Characteristics of Crohn’s disease

Age at diagnosis, n (%)

 ≤ 16 years

17–40 years

 > 40 years

4 (21)

7 (37)

8 (42)

Location of disease, n (%)

ileum

colon

ileum and colon

2 (11)

4 (21)

13 (68)

Disease behaviour, n (%)

inflammatory

structuring

penetrating

11 (58)

5 (26)

3 (16)

Peri-anal disease, n (%)

6 (32)

Duration of disease, years

15 (2–54)

Disease activity

 

Flare following PGA, n (%)

4 (21)

CRP, mg/L

2.2 (0.9–20)

Medication

 

Subcutaneous use, n (%)

12 (63)

Duration of MTX use, months

77 (7–202)

Co-therapy with TNF-α inhibitor, n (%)

7 (37)

MTX dose, mg/week, n (%)

15

10; 20; 25

16 (84)

1 (5); 1 (5); 1 (5)

Folic acid dose, mg/week, n (%)

15

10

5

1.5

11 (58)

1 (5)

6 (32)

1 (5)

  1. Data presented as median (minimum—maximum) unless stated otherwise
  2. Units are italicised